SCHEMBL27189556

SCHEMBL27189556

COc1cc(F)c(C)c2[nH]cc(CCN(C)C)c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 5/20 0.54
▸ HTR6 P50406 4/20 0.50
▸ HTR2A P28223 3/20 0.46
▸ HTR2C P28335 2/20 0.46
▸ HTR2B P41595 2/20 0.46
▸ HTR3E A5X5Y0 1/20 0.41
▸ HTR3B O95264 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ HTR1D P28221 1/20 0.41
▸ HTR1B P28222 1/20 0.41
▸ HTR1E P28566 1/20 0.41
▸ HTR1F P30939 1/20 0.41
▸ HTR7 P34969 1/20 0.41
▸ HTR3A P46098 1/20 0.41
▸ HTR5A P47898 1/20 0.41
▸ MTNR1A P48039 1/20 0.41
▸ MTNR1B P49286 1/20 0.41
▸ HTR4 Q13639 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25029941 0.84 HTR1A (0.48) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL25907490 0.83 HTR1A (0.55) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL25029922 0.81 HTR1A (0.67) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL30483753 0.81 HTR1A (0.67) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL25282377 0.81 HTR1A (0.67) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL25791525 0.77 HTR1A (0.42) HTR1AHTR2AHTR2CHTR2BHTR1D
SCHEMBL25436824 0.77 HTR6 (0.60) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL12559104 0.76 HTR1A (0.67) HTR1AHTR6HTR2AHTR2CHTR2B
SCHEMBL25030358 0.75 HTR1D (0.41) HTR1AHTR2AHTR2CHTR2BHTR1D
SCHEMBL24420538 0.75 HTR1A (0.69) HTR1AHTR6HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059217-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF BRIGHT MINDS BIOSCIENCES INC. (CA) 2025-02-20 — — US disclosed
CN-117897376-A Heterocyclic compounds and process for preparing same 光明智慧生物科学公司 2024-04-16 — — CN disclosed
EP-4347561-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF Bright Minds Biosciences Inc. (CA) 2024-04-10 — — EP disclosed
WO-2022246554-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF BRIGHT MINDS BIOSCIENCES INC. (CA) 2022-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059217-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF OPRL1, OPRK1, CNR2 HTR1A 306/4885HTR6 410/4885HTR2A 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback